Home Healthcare Pharmaceuticals Skin Cancer Diagnostics and Therapeutics Market

Skin Cancer Diagnostics and Therapeutics Market Size, Share & Trends Analysis Report By Type (Diagnostics, Therapeutics), By Cancer Type (Melanoma, Non-melanoma) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 09, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Skin Cancer Diagnostics and Therapeutics Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Diagnostics
      1. Dermatoscopy
      2. Biopsy
      3. Genetic Tests
      4. Others
    2. Therapeutics
      1. Chemotherapy
      2. Immunotherapy
      3. Targeted Therapy
      4. Radiotherapy
      5. Others
  2. Skin Cancer Diagnostics and Therapeutics Market, By Cancer Type 2022-2034 (USD MILLION/ Units)
    1. Melanoma
    2. Non-melanoma
  3. Regional Skin Cancer Diagnostics and Therapeutics Market
    1. North America
      1. North America Skin Cancer Diagnostics and Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
      2. North America Skin Cancer Diagnostics and Therapeutics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Melanoma
        2. Non-melanoma
      3. U.S.
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      4. Canada
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
    2. Europe
      1. Europe Skin Cancer Diagnostics and Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
      2. Europe Skin Cancer Diagnostics and Therapeutics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Melanoma
        2. Non-melanoma
      3. U.K.
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      4. Germany
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      5. France
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      6. Spain
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      7. Italy
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      8. Russia
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      9. Nordic
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      10. Benelux
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      11. Rest of Europe
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
    3. APAC
      1. APAC Skin Cancer Diagnostics and Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
      2. APAC Skin Cancer Diagnostics and Therapeutics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Melanoma
        2. Non-melanoma
      3. China
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      4. Korea
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      5. Japan
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      6. India
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      7. Australia
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      8. Taiwan
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      9. South East Asia
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      10. Rest of Asia-Pacific
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
    4. Middle East and Africa
      1. Middle East and Africa Skin Cancer Diagnostics and Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
      2. Middle East and Africa Skin Cancer Diagnostics and Therapeutics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Melanoma
        2. Non-melanoma
      3. UAE
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      4. Turkey
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      5. Saudi Arabia
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      6. South Africa
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      7. Egypt
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      8. Nigeria
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      9. Rest of MEA
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
    5. LATAM
      1. LATAM Skin Cancer Diagnostics and Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
      2. LATAM Skin Cancer Diagnostics and Therapeutics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Melanoma
        2. Non-melanoma
      3. Brazil
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      4. Mexico
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      5. Argentina
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      6. Chile
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      7. Colombia
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
      8. Rest of LATAM
        1. Diagnostics
          1. Dermatoscopy
          2. Biopsy
          3. Genetic Tests
          4. Others
        2. Therapeutics
          1. Chemotherapy
          2. Immunotherapy
          3. Targeted Therapy
          4. Radiotherapy
          5. Others
        3. Melanoma
        4. Non-melanoma
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.